Evidence map›Paper›PMID 41142606›Full record

ArticleFrontiers in oncology2025

Dextran sulfate inhibits the invasion, migration, and programmed death-ligand 1 expression in human gastric cancer cells by affecting the M2 tumor-associated macrophage polarization.

Jing Shang, Yuanyi Xu, Yuejia Tao, Bing Li, Mengqi Li, Jiaxin Guo, Lvjun Yan, Yunning Huang, Qian Ma

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jing Shang *Oncology Hematology Department, University-Town Hospital of Chongqing Medical University, Chongqing, China.
Yuanyi Xu *Third Clinical Medical College, Ningxia Medical University, Yinchuan, China.
Yuejia TaoThird Clinical Medical College, Ningxia Medical University, Yinchuan, China.
Bing LiThird Clinical Medical College, Ningxia Medical University, Yinchuan, China.
Mengqi LiThird Clinical Medical College, Ningxia Medical University, Yinchuan, China.
Jiaxin GuoThird Clinical Medical College, Ningxia Medical University, Yinchuan, China.
Lvjun YanOncology Hematology Department, University-Town Hospital of Chongqing Medical University, Chongqing, China.
Yunning HuangThird Clinical Medical College, Ningxia Medical University, Yinchuan, China.
Qian MaSchool of Life Sciences, Ningxia University, Yinchuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The aim of this study was to investigate the role of dextran sulfate (DS) in M0-to-M2 macrophage polarization and its effect on programmed death-ligand 1 (PD-L1) expression, invasion, migration, proliferation, and apoptosis of human gastric cancer cells (HGCCs) through its action on M2 tumor-associated macrophages (M2-TAMs). Methods: The effects of DS on M0-to-M2 macrophage polarization and HGCC behavior were examined. CD163 expression was analyzed to determine macrophage polarization, whereas HGCC proliferation, apoptosis, migration, and invasion and PD-L1 expression were quantified. The effect of DS on tumor development was evaluated in an Results: DS inhibited M0-to-M2 macrophage polarization and HGCC proliferation, invasion, and migration while increasing apoptosis and decreasing PD-L1 expression. DS decreased the number and the size of metastatic tumor nodules in nude mice while decreasing CD163 expression. CD163 expression is positively associated with PD-L1 expression ( Conclusion: DS inhibits the macrophage transition to the M2 phenotype, leading to a reduced PD-L1 expression and HGCC proliferation, invasion, and migration while increasing cell death.

Indexed as

dextran sulfateinvasion and migrationM2 tumor-associated macrophagesprogrammed death-ligand 1proliferation and apoptosis

Identifiers

PMID41142606
PMCPMC12549276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.